QS Investors’s Editas Medicine EDIT Stock Holding History

QS Investors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,350	Closed	-$291K	–	1210
2020 Q3	$291K	Sell	10,350 -81,260	-89%	-$2.65M	﹤0.01%	934
2020 Q2	$2.71M	Hold	91,610	–	–	0.04%	377
2020 Q1	$1.82M	Hold	91,610	–	–	0.03%	454
2019 Q4	$2.7M	Sell	91,610 -1,100	-1%	-$27.5K	0.03%	486
2019 Q3	$2.11M	Hold	92,710	–	–	0.02%	550
2019 Q2	$2.29M	Buy	+92,710	New	+$2.21M	0.02%	535

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

QS Investors's EDIT Position: Q4 2020 in Review

QS Investors sold out of Editas Medicine (EDIT) in Q4 2020, closing a stake of 10,350 shares — an estimated $291K sold.

QS Investors first reported a position in EDIT in Q2 2019 and held it in 6 quarters. The position peaked at $2.71M in Q2 2020. 311 funds tracked by Wall St. Rank hold EDIT as of Q4 2020.

QS Investors reported no remaining Editas Medicine position as of Q4 2020 after selling out during the quarter.
QS Investors sold 10,350 Editas Medicine shares in Q4 2020, an estimated $291K.
QS Investors first reported a position in Editas Medicine in Q2 2019 and held it in 6 quarters.
QS Investors's Editas Medicine position peaked at $2.71M in Q2 2020.
311 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.